Abstract
Type 2 diabetes (T2D) is a global public health concern due to its increasing prevalence. Risk assessment and early detection of T2D are vital in improving individuals’ health, reducing the burden on health insurance, and enhancing well-being. This study leverages artificial intelligence (AI), specifically eXtreme Gradient Boosting (XGBoost), to develop predictive models for T2D based on genetic and medical imaging data. The study aims to establish a prediction model and identify high-risk subgroups for T2D within a cohort of 68,911 Taiwan Biobank (TWB) participants. The approach integrates the Polygenic Risk Score (PRS) and Multi-image Risk Score (MRS) with demographic factors and environmental exposures to assess T2D risk. The model’s performance is evaluated using the Area Under the Receiver Operating Curve (AUC). Results demonstrate that genetic information alone is insufficient for accurate T2D prediction (AUC = 0.73), whereas medical imaging data, including abdominal ultrasonography, vertebral artery ultrasonography, bone density scan, and electrocardiography, significantly improves prediction accuracy (AUC = 0.89). The best-performing model integrates genetic, medical imaging, and demographic variables (AUC = 0.94), successfully identifying subgroups at high risk of developing T2D. The study also presents an online risk assessment website for T2D. In summary, this research represents the first integration of genetic and medical imaging data for T2D risk assessment. The genetic-only model outperforms previous genetic prediction studies, and integrating genetic and medical imaging information significantly enhances prediction. By utilizing artificial intelligence to analyze genetic, medical imaging, and demographic factors, this study contributes to early detection and precision health of T2D.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by research grants from the Academia Sinica (AS-PH-109-01 and AS-SH-112-01).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Institute Review Board of Academia Sinica gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript
https://hcyang.stat.sinica.edu.tw/software/T2D_web/header.php
